Overview
- The U.S. Food and Drug Administration cleared Elecsys pTau217 on Aug. 24, 2026 as a blood test to help assess the likelihood of Alzheimer’s-related amyloid pathology in people 55 or older with cognitive symptoms.
- The test measures phosphorylated tau 217 (pTau‑217) and reports positive, intermediate, or negative results to indicate higher, uncertain, or lower likelihood of amyloid pathology.
- Roche says the assay runs on more than 4,500 existing cobas laboratory analyzers and major reference labs including Labcorp and Quest plan to offer the test, with Labcorp promising nationwide availability in the coming months.
- Roche and partners stress the test is not a standalone diagnostic and results must be interpreted with clinical information; performance for predicting dementia progression or for monitoring treatment response has not been established.
- The clearance follows earlier FDA and European steps for blood biomarkers and could cut dependence on costly PET scans and invasive spinal taps, but real-world impact will hinge on pricing, reimbursement, clinician adoption, and confirmatory testing pathways.